Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 15 | 2023 | 255 | 2.610 |
Why?
|
| Ultrasonography | 15 | 2025 | 203 | 2.310 |
Why?
|
| Point-of-Care Systems | 6 | 2025 | 58 | 1.940 |
Why?
|
| Abscess | 4 | 2020 | 26 | 1.830 |
Why?
|
| Soft Tissue Infections | 3 | 2020 | 25 | 1.660 |
Why?
|
| Fibrinolytic Agents | 2 | 2025 | 58 | 1.530 |
Why?
|
| Humans | 53 | 2025 | 23210 | 1.350 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2020 | 18 | 1.220 |
Why?
|
| Anti-Bacterial Agents | 6 | 2021 | 363 | 1.170 |
Why?
|
| Shoulder Dislocation | 2 | 2022 | 87 | 1.170 |
Why?
|
| Heart Arrest | 2 | 2020 | 42 | 1.160 |
Why?
|
| Trachea | 4 | 2025 | 38 | 1.100 |
Why?
|
| Warfarin | 3 | 2022 | 25 | 0.950 |
Why?
|
| Intubation, Intratracheal | 4 | 2025 | 82 | 0.930 |
Why?
|
| Endovascular Procedures | 1 | 2025 | 27 | 0.880 |
Why?
|
| Thrombectomy | 1 | 2025 | 30 | 0.880 |
Why?
|
| Thrombolytic Therapy | 1 | 2025 | 44 | 0.870 |
Why?
|
| Retrospective Studies | 18 | 2023 | 2993 | 0.860 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 34 | 0.830 |
Why?
|
| Hyperkalemia | 2 | 2021 | 5 | 0.820 |
Why?
|
| Blood Coagulation Factors | 3 | 2022 | 19 | 0.820 |
Why?
|
| Drainage | 3 | 2020 | 36 | 0.820 |
Why?
|
| Fractures, Bone | 2 | 2022 | 70 | 0.810 |
Why?
|
| Esophagus | 3 | 2022 | 53 | 0.790 |
Why?
|
| Ventricular Fibrillation | 2 | 2020 | 13 | 0.770 |
Why?
|
| Hemorrhage | 2 | 2020 | 74 | 0.750 |
Why?
|
| Critical Illness | 3 | 2021 | 98 | 0.730 |
Why?
|
| Antiemetics | 1 | 2022 | 11 | 0.730 |
Why?
|
| Hypoglycemia | 2 | 2021 | 12 | 0.720 |
Why?
|
| Sympathomimetics | 1 | 2021 | 5 | 0.710 |
Why?
|
| Airway Management | 1 | 2021 | 15 | 0.700 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2020 | 11 | 0.700 |
Why?
|
| Emergency Medicine | 2 | 2020 | 93 | 0.700 |
Why?
|
| Ketamine | 1 | 2021 | 23 | 0.690 |
Why?
|
| Adult | 15 | 2025 | 6962 | 0.680 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 41 | 0.680 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 42 | 0.670 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 36 | 0.660 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2025 | 244 | 0.660 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 7 | 0.650 |
Why?
|
| Skin Diseases | 1 | 2020 | 21 | 0.650 |
Why?
|
| Phenytoin | 1 | 2020 | 5 | 0.650 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 15 | 0.650 |
Why?
|
| Documentation | 1 | 2020 | 20 | 0.650 |
Why?
|
| Bites and Stings | 1 | 2020 | 3 | 0.650 |
Why?
|
| Wound Infection | 1 | 2020 | 6 | 0.640 |
Why?
|
| Status Epilepticus | 1 | 2020 | 12 | 0.640 |
Why?
|
| Inappropriate Prescribing | 1 | 2020 | 5 | 0.640 |
Why?
|
| Male | 18 | 2023 | 12665 | 0.640 |
Why?
|
| Anticonvulsants | 1 | 2020 | 51 | 0.630 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 20 | 0.620 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 26 | 0.610 |
Why?
|
| Gonorrhea | 1 | 2019 | 6 | 0.600 |
Why?
|
| Chlamydia Infections | 1 | 2019 | 6 | 0.600 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 134 | 0.590 |
Why?
|
| Aftercare | 1 | 2019 | 22 | 0.590 |
Why?
|
| Glucagon | 1 | 2019 | 6 | 0.590 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 9 | 0.590 |
Why?
|
| Retinal Detachment | 1 | 2019 | 7 | 0.580 |
Why?
|
| Pulmonary Edema | 3 | 2023 | 21 | 0.580 |
Why?
|
| Female | 17 | 2023 | 13149 | 0.580 |
Why?
|
| Foreign Bodies | 1 | 2019 | 20 | 0.580 |
Why?
|
| Epistaxis | 1 | 2018 | 9 | 0.570 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 16 | 0.570 |
Why?
|
| Spinal Puncture | 1 | 2018 | 23 | 0.560 |
Why?
|
| Tranexamic Acid | 1 | 2018 | 17 | 0.560 |
Why?
|
| Skin Diseases, Infectious | 1 | 2018 | 6 | 0.550 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 257 | 0.540 |
Why?
|
| Anthrax | 1 | 2017 | 1 | 0.540 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 64 | 0.540 |
Why?
|
| Transportation of Patients | 1 | 2017 | 4 | 0.540 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 3 | 0.540 |
Why?
|
| Mass Casualty Incidents | 1 | 2017 | 5 | 0.530 |
Why?
|
| Health Resources | 1 | 2017 | 21 | 0.530 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 26 | 0.530 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 29 | 0.530 |
Why?
|
| Middle Aged | 13 | 2023 | 7983 | 0.490 |
Why?
|
| Anticoagulants | 3 | 2022 | 82 | 0.470 |
Why?
|
| Sensitivity and Specificity | 7 | 2025 | 445 | 0.470 |
Why?
|
| Azoles | 1 | 2014 | 1 | 0.430 |
Why?
|
| Tacrolimus | 1 | 2014 | 14 | 0.430 |
Why?
|
| Sirolimus | 1 | 2014 | 20 | 0.420 |
Why?
|
| Treatment Failure | 3 | 2020 | 126 | 0.420 |
Why?
|
| Antifungal Agents | 1 | 2014 | 35 | 0.420 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 113 | 0.400 |
Why?
|
| Atrial Fibrillation | 3 | 2020 | 98 | 0.390 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 104 | 0.380 |
Why?
|
| Treatment Outcome | 5 | 2020 | 2943 | 0.380 |
Why?
|
| Aged | 9 | 2025 | 7661 | 0.370 |
Why?
|
| Algorithms | 1 | 2014 | 305 | 0.370 |
Why?
|
| Prospective Studies | 5 | 2023 | 1512 | 0.360 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2021 | 7 | 0.340 |
Why?
|
| Metoprolol | 3 | 2020 | 5 | 0.340 |
Why?
|
| Diltiazem | 3 | 2020 | 7 | 0.340 |
Why?
|
| Pharmacists | 2 | 2021 | 16 | 0.330 |
Why?
|
| Intestinal Obstruction | 2 | 2023 | 11 | 0.330 |
Why?
|
| Intensive Care Units | 3 | 2021 | 234 | 0.320 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2020 | 27 | 0.300 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 112 | 0.300 |
Why?
|
| Insulin | 2 | 2021 | 77 | 0.300 |
Why?
|
| Heart Failure | 2 | 2018 | 141 | 0.250 |
Why?
|
| International Normalized Ratio | 3 | 2022 | 17 | 0.240 |
Why?
|
| Nausea | 2 | 2023 | 24 | 0.230 |
Why?
|
| Vomiting | 2 | 2023 | 19 | 0.230 |
Why?
|
| Child | 2 | 2020 | 1160 | 0.230 |
Why?
|
| Chicago | 2 | 2019 | 847 | 0.230 |
Why?
|
| Point-of-Care Testing | 2 | 2023 | 27 | 0.230 |
Why?
|
| Bias | 1 | 2025 | 24 | 0.220 |
Why?
|
| Intracranial Hemorrhages | 1 | 2025 | 11 | 0.220 |
Why?
|
| Diverticulitis | 1 | 2025 | 7 | 0.220 |
Why?
|
| Nasal Cavity | 2 | 2021 | 31 | 0.210 |
Why?
|
| Nystagmus, Pathologic | 1 | 2023 | 2 | 0.200 |
Why?
|
| Potassium | 2 | 2021 | 59 | 0.200 |
Why?
|
| Dizziness | 1 | 2023 | 17 | 0.200 |
Why?
|
| Vancomycin | 2 | 2021 | 51 | 0.200 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 162 | 0.200 |
Why?
|
| Blood Glucose | 2 | 2021 | 104 | 0.190 |
Why?
|
| Eye | 1 | 2022 | 6 | 0.190 |
Why?
|
| Metoclopramide | 1 | 2022 | 4 | 0.180 |
Why?
|
| Thrombosis | 2 | 2020 | 51 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 235 | 0.180 |
Why?
|
| Neuroimaging | 1 | 2022 | 105 | 0.180 |
Why?
|
| Cystitis | 1 | 2021 | 11 | 0.170 |
Why?
|
| Stroke Volume | 2 | 2018 | 41 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 27 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 31 | 0.170 |
Why?
|
| Young Adult | 2 | 2017 | 1659 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 15 | 0.170 |
Why?
|
| Publications | 1 | 2020 | 13 | 0.160 |
Why?
|
| Hypercalcemia | 1 | 2020 | 6 | 0.160 |
Why?
|
| Calcitonin | 1 | 2020 | 9 | 0.160 |
Why?
|
| Cardiovascular Agents | 1 | 2020 | 22 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2020 | 13 | 0.160 |
Why?
|
| Piracetam | 1 | 2020 | 7 | 0.160 |
Why?
|
| Diphosphonates | 1 | 2020 | 16 | 0.160 |
Why?
|
| Publishing | 1 | 2020 | 29 | 0.160 |
Why?
|
| Benzodiazepines | 1 | 2020 | 45 | 0.160 |
Why?
|
| Blood Coagulation | 1 | 2020 | 20 | 0.160 |
Why?
|
| Dogs | 1 | 2020 | 136 | 0.160 |
Why?
|
| Cellulitis | 1 | 2020 | 10 | 0.160 |
Why?
|
| Seizures | 1 | 2020 | 62 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 210 | 0.150 |
Why?
|
| Blood Pressure | 1 | 2020 | 171 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 60 | 0.150 |
Why?
|
| Physical Examination | 1 | 2020 | 87 | 0.150 |
Why?
|
| Mass Screening | 1 | 2021 | 162 | 0.150 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2019 | 3 | 0.150 |
Why?
|
| Chlamydia trachomatis | 1 | 2019 | 5 | 0.150 |
Why?
|
| Sepsis | 1 | 2020 | 74 | 0.150 |
Why?
|
| Shock | 1 | 2019 | 5 | 0.150 |
Why?
|
| Midodrine | 1 | 2019 | 3 | 0.150 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 155 | 0.150 |
Why?
|
| Bezoars | 1 | 2019 | 2 | 0.150 |
Why?
|
| Peristalsis | 1 | 2019 | 11 | 0.150 |
Why?
|
| Electronic Health Records | 1 | 2019 | 64 | 0.150 |
Why?
|
| Manipulation, Orthopedic | 1 | 2019 | 7 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 192 | 0.150 |
Why?
|
| Administration, Topical | 1 | 2018 | 14 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 314 | 0.150 |
Why?
|
| Capnography | 1 | 2018 | 8 | 0.140 |
Why?
|
| Lung | 3 | 2023 | 141 | 0.140 |
Why?
|
| Time Factors | 2 | 2021 | 1264 | 0.140 |
Why?
|
| Bacillus anthracis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Bioterrorism | 1 | 2017 | 3 | 0.140 |
Why?
|
| Neoplasms | 1 | 2020 | 219 | 0.140 |
Why?
|
| Ciprofloxacin | 1 | 2017 | 11 | 0.140 |
Why?
|
| Disaster Planning | 1 | 2017 | 7 | 0.130 |
Why?
|
| Length of Stay | 1 | 2019 | 298 | 0.130 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 13 | 0.130 |
Why?
|
| Doxycycline | 1 | 2017 | 16 | 0.130 |
Why?
|
| Bandages | 1 | 2017 | 4 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2018 | 227 | 0.130 |
Why?
|
| Intestine, Small | 1 | 2017 | 30 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 294 | 0.130 |
Why?
|
| Illinois | 1 | 2017 | 224 | 0.130 |
Why?
|
| Pain Measurement | 1 | 2018 | 412 | 0.120 |
Why?
|
| Infant | 1 | 2018 | 483 | 0.120 |
Why?
|
| Child, Preschool | 1 | 2018 | 570 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2019 | 1467 | 0.110 |
Why?
|
| Voriconazole | 1 | 2014 | 10 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 6 | 0.110 |
Why?
|
| Fluconazole | 1 | 2014 | 7 | 0.110 |
Why?
|
| Mycoses | 1 | 2014 | 17 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 19 | 0.100 |
Why?
|
| Triazoles | 1 | 2014 | 28 | 0.100 |
Why?
|
| Animals | 1 | 2020 | 3302 | 0.100 |
Why?
|
| Adolescent | 1 | 2017 | 1884 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 40 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 3865 | 0.090 |
Why?
|
| Acute Disease | 2 | 2025 | 163 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 599 | 0.090 |
Why?
|
| Professional Role | 2 | 2021 | 28 | 0.080 |
Why?
|
| Administration, Intravenous | 2 | 2019 | 22 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 315 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 633 | 0.060 |
Why?
|
| Vertigo | 1 | 2023 | 6 | 0.050 |
Why?
|
| Pleura | 1 | 2023 | 8 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 23 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2025 | 189 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2022 | 104 | 0.040 |
Why?
|
| Cadaver | 1 | 2022 | 284 | 0.040 |
Why?
|
| Linezolid | 1 | 2021 | 4 | 0.040 |
Why?
|
| Penicillanic Acid | 1 | 2020 | 3 | 0.040 |
Why?
|
| Piperacillin | 1 | 2020 | 3 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 147 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 104 | 0.040 |
Why?
|
| Medical Records | 1 | 2020 | 28 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 52 | 0.040 |
Why?
|
| Critical Care | 1 | 2021 | 97 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 110 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 137 | 0.040 |
Why?
|
| Pandemics | 1 | 2021 | 207 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 19 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 357 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 288 | 0.040 |
Why?
|